In animal experiments, TSME significantly enhanced the efficacy of αPD-1 monoclonal antibody by remodeling the tumor immune microenvironment (TME): The combination therapy group exhibited increased infiltration of CD8+ and CD4+ T cells (Figures 2a, b) and reduced proportions of immunosuppressive Treg cells (Figure 2c). Here, CD8A is linked to neoplasm.